We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Medical Center Collaborates with GenomeQuest

By LabMedica International staff writers
Posted on 14 Jan 2013
Print article
GenomeQuest, Inc. (Westborough, MA, USA) a leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA), a Harvard Medical School teaching hospital, are entering into a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School, on December 20, 2012, in Boston (MA, USA).

GenomeQuest will provide whole-genome data management and analysis capabilities for all next-generation sequencing projects in BIDMC’s dept. of pathology. GenomeQuest will also provide application programming interface (API) access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop clinical grade annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence, and annotation management, and integration into health care Information Technology (IT) systems.

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly $500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” explained BIDMC chief of pathology Jeffrey Saffitz, MD, PhD. “The BIDMC pathology department is already a national leader in the development and application of genomics for personalized medicine, having launched its Genomic Medicine Training Initiative one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. The core technology of GenomeQuest is the GQ-Engine–a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multigenome scale.

Related Links:
GenomeQuest, Inc.
Beth Israel Deaconess Medical Center

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Centrifuge
Centrifuge 5430/ 5430 R
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.